Suzhou Basecare expects H1 loss attributable to shareholders to narrow 39.5%-43.2% to RMB 69 million-RMB 73.5 million

• Suzhou Basecare guided for revenue of RMB 125.7 million to RMB 130.8 million for H1 2026, up 24%-29% from RMB 101.3 million.
• Loss attributable to equity shareholders seen at RMB 69 million to RMB 73.5 million, down 39.5%-43.2% year over year.
• Negative EBITDA forecast at RMB 44.4 million to RMB 49 million, narrowing 46.9%-51.9% from a year earlier.
• Outlook supported by PGT market expansion, including NMPA Class III registrations for a PGT-A kit in March 2026, PGT-M kit in April 2026.
• Commercial momentum also tied to NMPA market launch for Gems culture media, including one-step embryo culture medium approval in February 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Basecare Medical Corp. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260816-12285821), on August 16, 2026, and is solely responsible for the information contained therein.